Navigation Links
Regado Biosciences, Inc. Adds World-Class Interventional Cardiologist and Researcher to Medical Advisory Board
Date:12/17/2013

BASKING RIDGE, N.J., Dec. 17, 2013 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that Deepak L. Bhatt, M.D., M.P.H., F.A.C.C., F.A.H.A., has joined the Company's Medical Advisory Board.  Regado will benefit from Dr. Bhatt's expertise in cardiovascular intervention and years of experience leading international cardiovascular clinical trials, as the Company actively enrolls patients in its Phase 3 REGULATE-PCI study and positions REG-1 as a potential standard of care for anticoagulant use in percutaneous coronary intervention procedures.

Dr. Bhatt commented, "I have always been attracted to advanced technologies with applications in cardiovascular intervention because of the potential to improve patient care.  I look forward to exploring the new possibilities for managing patients safely and effectively through technological advances in controllable drug systems."

David J. Mazzo, Ph.D., Chief Executive Officer of Regado Biosciences, stated, "Dr. Bhatt is a world-class clinician and cardiovascular researcher, and we are honored to have him join our Medical Advisory Board.  His academic and clinical contributions have advanced the field significantly, and we look forward to gaining from his expert insight as we advance the ongoing Phase 3 REGULATE-PCI study of REG1."

Dr. Bhatt is currently Executive Director of Interventional Cardiovascular Programs at Brigham and Women's Hospital Heart and Vascular Center.  He is also a Senior Physician at Brigham and Women's Hospital, and Professor of Medicine at Harvard Medical School.  He has completed fellowships in interventional cardiology and cerebral and peripheral vascular intervention, authored or co-authored over 600 publications, and has been listed in Best Doctors in America from 2005 to the present.  He was the principal or co-principal investigator for a number of late-stage international cardiovascular clinical trials.

Dr. Bhatt was a National Merit Scholar at MIT before receiving his MD from Cornell University and completing his Masters in Public Health at Harvard University.  He performed his internship and residency in internal medicine at the Hospital of the University of Pennsylvania and completed his cardiovascular training at Cleveland Clinic.

ABOUT REGADO BIOSCIENCES
Regado Biosciences, Inc. is a biopharmaceutical company focused on the development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications.  Regado is pioneering the development of two-component drug systems consisting of a therapeutic aptamer and its specific active control agent.  The company's lead product candidate, REG1, is a two-component system consisting of pegnivacogin, an anticoagulant aptamer specifically targeting coagulation Factor IXa, and its complementary oligonucleotide active control agent, anivamersen. REG1 is currently being evaluated in the REGULATE-PCI trial, a world-wide Phase 3 study enrolling 13,200 patients with acute coronary syndromes (ACS) undergoing a percutaneous coronary intervention (PCI), a hospital-based procedure used to mechanically open or widen obstructed coronary arteries.  Regado's actively controllable product candidates have the potential to improve patient outcomes, enhance the patient experience and reduce overall treatment costs.  More information can be found at www.regadobio.com.

For more information on REGULATE-PCI, please visit:
http://www.clinicaltrials.gov/ct2/show/NCT01848106?term=Regado&rank=1

Contact:
Tiberend Strategic Advisors, Inc.

Investors - Joshua Drumm, Ph.D.
jdrumm@tiberend.com; (212) 375-2664
Media - Andrew Mielach
amielach@tiberend.com; (212) 375-2694


'/>"/>
SOURCE Regado Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regado Biosciences, Inc. to Present at the 2012 Wedbush PacGrow Life Sciences Conference in New York, NY
2. Regado Biosciences, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference in Boston, MA
3. Regado Biosciences, Inc. to Present at the UBS Global Life Sciences Conference 2012 in New York, NY
4. Regado Biosciences, Inc. to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York, NY
5. Regado Biosciences, Inc. Announces Pricing of Initial Public Offering
6. Regado Biosciences, Inc. Announces Closing of Initial Public Offering
7. Regado Biosciences, Inc. Announces Third Quarter 2013 Results
8. Regado Biosciences, Inc. Adds Global Pharmaceutical Business Veteran to Board of Directors
9. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
10. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
11. Founded by Enlight Biosciences, KNODE partners with AstraZeneca and Other Partners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2019)... BEVERLY HILLS, Calif. (PRWEB) , ... November 20, 2019 , ... The Lifedriven Foundation along ... its Mixing it Up with the Champs event from 8 to 11 p.m. on Friday, ... Vegas. This fundraising event will take place on the eve of the PBC Heavyweight Title ...
(Date:11/20/2019)... ... November 20, 2019 , ... “Analysis of the Biofield ... Assay” by Maria Isabel Aguilar has been named No. 1 International Best Seller ... Research, Holistic, Mind-Body Medicine, Allied Health Professions, and Energy Healing. , The aim ...
(Date:11/19/2019)... ... ... “Protective Role of the Biofield Energy Treated Test Formulation on Vital Organs ... Best Seller on Amazon in the USA, Canada, and United Kingdom in 19 categories ... named a hot new release in multiple categories in the USA, Canada, and United ...
Breaking Medicine Technology:
(Date:11/21/2019)... , ... November 21, 2019 , ... ... chall@charteroak.edu; 860-515-3889 , Middlesex Health Care Awarded the Golden Acorn by the Charter ... , The Foundation for Charter Oak State College, Connecticut’s public online college, recently ...
(Date:11/21/2019)... ... November 21, 2019 , ... PointClickCare, ... post-acute care and senior care industry, has named Richter as its 2019 ... Richter and PointClickCare on targeted training activities related to Medicare Patient-Driven Payment ...
(Date:11/20/2019)... ... November 20, 2019 , ... Fujirebio ... and Drug Administration (FDA) clearance of the company’s Lumipulse® G whole PTH Assay ... a hormone secreted by the parathyroid glands; which are four small glands located ...
(Date:11/20/2019)... , ... November 20, 2019 , ... ... Health Specific Biomarkers Using Cell Line Study” by Ariadne Esmene Afaganis has been ... Kingdom in many categories including Nervous System, Molecular Biology, Energy Healing, Public Health, ...
(Date:11/19/2019)... (PRWEB) , ... November 19, 2019 , ... It was ... marathon with a bike ride along the Charles River in Boston. Days later, Bernie ... to him, yet he struggled to know exactly who all of them were. For ...
Breaking Medicine News(10 mins):